JULY 2022LIFE SCIENCES REVIEW8ormioli Pharma is a global pharmaceutical packaging manufacturer marketing glass and plastic vials, containers and closures in over 100 countries around the world. Featuring 9 plants in Italy, France and Germany, and over 1,300 employees, the company started an innovation program in early 2019 named Bormioli Pharma Invents, based on an Open Innovation approach.The Open Innovation approach is a breakthrough for the pharma packaging industry, which has traditionally been bound to internal R&D departments and processes that are neither easily accessible nor open to communication with external stakeholders.Open Innovation was first theorized by Henry Chesbrough in 2004. He described the innovation models of cutting-edge companies in the 80s and the 90s and identified a common path: "Open Innovation". Instead of setting up an exclusive internal process for knowledge development, Chesbrough understood that companies found developing a distributed ecosystem to be more efficient, where know-how can be identified and developed in collaboration with internal and external players, using the internal know-how to generate additional value through new business modelsThe advantages are: a significant cost reduction coming from inbound open innovation, reducing development costs, and generating a new revenue stream from spin offs and licenses. All of these savings significantly change the Innovation ROI.In 2019, Bormioli Pharma turned theory into practice. First, we identified four opportunities for growth in our industry, four strategic pillars that we repute to be the main drivers of change in the pharmaceutical primary packaging market. These are: usability, connectivity, traceability and sustainability.We developed an Open Innovation System around these pillars, which combines internal R&D assets with external contributors, fostering collaboration projects and identifying common ways to generate value.By Federico Piutti, Innovation Manager, Bormioli PharmaAN OPEN INNOVATION APPROACH APPLIED TO THE PHARMACEUTICAL INDUSTRYFederico PiuttiIN MY OPINION
< Page 7 | Page 9 >